Erratum to: Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

Ítems similars

• Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
  per: Pimentel, M., et al.
  Publicat: (2017)
• Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin
  per: DuPont, Herbert L., et al.
  Publicat: (2016)
• Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
  per: Lembo, Anthony, et al.
  Publicat: (2020)
• Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
  per: Cash, Brooks D., et al.
  Publicat: (2017)
• Rifaximin: Irritable Bowel Syndrome
  per: Generali, Joyce A., et al.
  Publicat: (2014)